Ondine Biomedical Share Discussion Threads

[marvelman] 16/5/2024 11:38

Pots and kettles come to mind reading that Purple. You surely must admit to being, at the very least, inconsistent with your view of this company.

[z1co] 16/5/2024 11:37

A groundbreaking study in the UK has revealed a significant reduction in the need for antibiotics after sinus surgeries, thanks to a pioneering treatment called Steriwave.

Professor Claire Hopkins, a specialist in rhinology from King's College London and a consultant ENT surgeon at Guy's & St Thomas' NHS Foundation Trust, conducted the analysis.

She found that incorporating Steriwave for nasal decolonisation before endoscopic sinus surgery led to a 77% decrease in antibiotic usage. This means antibiotic use among her patients fell from 22% to just under 5%.

Since 2021, Professor Hopkins has been applying Steriwave as a standard procedure for her patients at London Bridge Hospital.

She said: "I was amazed that studies show that by treating the nose you can reduce spinal surgical site infections - so it seemed an ideal way to reduce the risk of post-operative infection after nasal surgery.

"I have seen a significant reduction in post-operative infections requiring antibiotics, which is good for the patients, reducing the risk of antibiotic-related side effects, and important to help prevent ever-increasing antibiotic resistance.

"It needs formal controlled studies to further evaluate the effectiveness but I am impressed with the difference that I have seen in my practice."

Ondine CEO Carolyn Cross welcomed the findings, which build on a significant and growing data set being compiled around the real-world use of Steriwave.

She told investors: "In an era of rising drug resistance, antibiotic stewardship is of great importance. Sinus surgery is typically associated with high rates of routine post-operative antibiotic prescribing in order to reduce the risk of post-operative infection.

"Reducing antibiotic usage is important to curb rising antimicrobial resistance and preserve antibiotics' effectiveness when there is no other solution.

"We are pleased to be supporting Professor Hopkins' development and adoption of important new infection control procedures that enable a marked reduction in antibiotic use in sinus surgery patients."

[z1co] 14/5/2024 12:27

In Q1 several hospitals announced expansions to include other surgical indications.

The Company is also benefitting from significantly reduced sales cycle times, lower new client acquisition costs and improved margins resulting from lower cost of goods and higher product pricing.

Also in the last quarter five hospitals outside of Canada have take up Steriwave , in the UK , Spain and Australia.

Steriwave in 2024 is starting to gain traction and more hospitals will start to replace the standard Mupirocin with Steriwave.

[purple11] 14/5/2024 05:52

considering how many hospitals there are in the world, Steriwave is used in a miniscule number of them.

wether it ever gains traction and spreads throughout the estate is a bit like a pipe dream.
in the 10 years it has been out for so far its used in a tiny number of hospitals and makes no money

in the meantime continual heavy dilution here could see a total collapse in the shareprice to 1p.

its clearly still in a downtrend and chancers like Zico will be long gone ,leaving you holding the baby as soon as it drops 10%so take their posts with a pinch of salt.he is not to be trusted.atb

[purple11] 13/5/2024 14:59

absolutely no interest here from the Retail community thus far.......

[z1co] 13/5/2024 10:02

Thanks marvelman

As well the 24 hospitals Steriwave has also been authorised to be used in the UK by HCA Healthcare UK.

HCA Healthcare is the largest private healthcare provider in the world, and one of the leading private healthcare providers in the UK, where it operates over 30 healthcare facilities.

Momentum for Steriwave in 2024 is picking up very strongly.

[marvelman] 13/5/2024 07:35

BBC news...well spotted Zico

[purple11] 12/5/2024 23:37

"50% up from the previous year-end and four times the number at the beginning of 2023."



very pumpy type of language used by OBI

when in fact the rollout so far is pitiful


be careful

[z1co] 12/5/2024 15:09

Take up of Steriwave is finally gaining real traction in 2024.

Ondine ended 2023 with 16 hospital deployments, up from six at the prior year end. This momentum has continued with eight additional hospital deployments in Q1 2024, bringing the total to 24 hospitals, 50% up from the previous year-end and four times the number at the beginning of 2023.

[jailbird] 12/5/2024 13:13

Excluding the Phase 3 clinical trial execution and related costs which are subject to further funding, the net proceeds of the Fundraising and strategic cost management will provide runway for the Company through to at least mid Q3 2024. This may be further extended through the issue of further New Common Shares in connection with future fundraisings, and/or the attainment of a higher value of commercial sales than is currently forecast.It just shows the coast of executing phase 3 trials are very high .Will need more money in Q3 to execute trials With shareholders being diluted , it makes it difficult to time buying again .Results of trials will be latter part of next year. It is a shame current contracts are tiny in revenues so no cashflow coming in

[z1co] 12/5/2024 11:51

Ondine Biomedical says progress has surpassed management expectations
Published: 07:39 15 Mar 2024 GMT

Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF), a specialist in light-activated antimicrobial treatments, said its commercial progress so far this year has been ahead of management's expectations, buoyed by the deployment of its Steriwave technology in eight new healthcare facilities.

It brings the total number of hospitals using Steriwave to 22, nearly quadruple the number a year ago.

The Ottawa Hospital (TOH) is increasing its utilisation of Steriwave, extending its application from spinal to orthopaedic and vascular surgeries, anticipating its use in approximately 2,600 surgical procedures annually — a threefold increase from its pilot phase.

This decision follows a comprehensive cost-benefit analysis, highlighting Steriwave's effectiveness in reducing post-surgical infection rates and associated healthcare costs.

In addition to the domestic expansion, Ondine's international footprint is growing, with the first three hospitals in Spain, including Hospital Universitario La Paz (HULP) in Madrid, initiating a paid pilot on the Ondine technology.

This development is part of a strategy to address the rising global challenge of antibiotic resistance and the associated healthcare costs, as evidenced by recent findings showing a net saving of nearly C$2,600 per spine surgery patient treated with Steriwave and chlorhexidine skin decolonisation.

The expansion also includes the Sturgeon Community Hospital in Alberta, part of Canada's largest integrated health system, and the Nanaimo Regional General Hospital in British Columbia.

Both institutions have adopted Steriwave to reduce surgical site infections (SSIs) in various surgical procedures, further demonstrating the technology's applicability and efficacy across different medical specialties.

Ondine Biomedical is currently engaging with medical device distributors to broaden Steriwave's commercial reach.

[z1co] 12/5/2024 09:29

Nasal laser treatment rolled out in West Yorkshire after trial

Published 9 April

By Rachel Russell

Patients in West Yorkshire have become the first in the country to access a new pre-surgery laser treatment, following a successful trial.

Mid Yorkshire Teaching NHS Trust has started to roll out Steriwave on those coming in for hip and knee surgery.

The treatment involves a probe shining a red light into patients' nostrils to kill off bacteria which cause surgical site infections.

Dr Stuart Bond called it an "important new technology".

"We are very excited to be the first Trust to be giving patients access to this important new technology which kills viruses, bacteria, and fungi with a five-minute treatment," Dr Bond, a consultant antimicrobial pharmacist and director of innovation, said.

The treatment was rolled out following a successful trial at Pontefract Hospital last year, with the aim of helping to prevent patients getting infections during surgery.

The NHS has previously said it hopes it could be an alternative to nasal antibiotics, which are currently given to patients before their surgery to prevent infections such as MRSA.

Carolyn Cross, chief executive officer at Ondine Biomedical, said: "We are delighted the Trust has adopted Steriwave, particularly as the NHS is seen around the world as a leader in antibiotic stewardship in response to the growing threat of antimicrobial resistance."

[z1co] 10/5/2024 07:50

In 2023, Ondine presented research at the 2023 International Consortium on Prevention & Infection Control (ICPIC) in Geneva, demonstrating that Steriwave was highly effective (>99.99% kills in 20 seconds) against both moderately drug-resistant (MDR) and extensively drug-resistant (XDR) bacteria.[2]

Ondine's Steriwave technology is already used in the UK in the NHS and extensively in hospitals across Canada to prevent HAIs. In 2024, hospitals in Spain became the first in the EU to adopt this groundbreaking technology. The prestigious Hospital Universitario La Paz (HULP), a large tertiary hospital in Madrid with 1,308 beds, is one of three Spanish hospitals using Steriwave.

[z1co] 10/5/2024 07:12

10/05/2024:

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

ECDC report shows HAIs are increasing antibiotic use

A third of microorganisms causing HAIs (healthcare-associated infections) were found to be resistant to antibiotics, leaving doctors with fewer effective treatment options for patients

Ondine Biomedical (LON: OBI): A recent report from the European Centre for Disease Prevention and Control (ECDC) helps underscore the need for Ondine's light-activated antimicrobial technology, a much-needed innovation in the face of growing antibiotic resistance. The report reveals an alarming increase in antibiotic use and rising resistance and finds that 4.3 million patients in EU/EEA hospitals are affected by healthcare-associated infections (HAIs). Ondine's technology offers a promising solution, now used across Canada and in the NHS. The technology kills all types of pathogens without causing resistance, addressing a critical gap in the fight against antimicrobial resistance (AMR).

The report, "Point prevalence survey of healthcare-associated infections and anti-microbial use in European acute care hospitals - 2022-2023", showed that antibiotic usage has increased since the last report in 2016-17. In 2022-23, 35.5% of patients were found to have received at least one antimicrobial agent, compared to 32.9% in 2016-17. This increase in antibiotic use is particularly concerning because one in three microorganisms causing HAIs were found to be resistant to antibiotics, leaving doctors with fewer options to treat patients effectively.

ECDC Director Dr. Andrea Ammon said: "Healthcare-associated infections pose a significant challenge to patient safety in hospitals throughout Europe. These recent numbers highlight the urgent need for further actions to mitigate this threat. By prioritising infection prevention and control policies and practices, as well as antimicrobial stewardship and improving surveillance, we can effectively combat the spread of these infections and protect the health of patients across the EU/EEA."

With the threat of antibiotic-resistant HAIs increasing year-on-year, there is a growing need for effective antimicrobials which do not generate resistance. Antimicrobial resistance (AMR) is responsible for 1.27 million deaths a year and is one of humanity's most urgent global public health threats.[1] Ondine's Steriwave light-activated antimicrobial technology is highly effective against all types of pathogens-viruses, bacteria and fungi-including those that cause HAIs, even those resistant to antibiotics.

Steriwave is a broad-spectrum light-activated antimicrobial that uses a patented photosensitizer and associated red light to destroy pathogens in the nose. The nose is a major reservoir of bacteria, fungi, and viruses, which can spread from there to cause serious infections. Unlike traditional antibiotics, Steriwave is immediately effective with a single five-minute treatment and does not trigger AMR.

In 2023, Ondine presented research at the 2023 International Consortium on Prevention & Infection Control (ICPIC) in Geneva, demonstrating that Steriwave was highly effective (>99.99% kills in 20 seconds) against both moderately drug-resistant (MDR) and extensively drug-resistant (XDR) bacteria.[2]

Ondine's Steriwave technology is already used in the UK in the NHS and extensively in hospitals across Canada to prevent HAIs. In 2024, hospitals in Spain became the first in the EU to adopt this groundbreaking technology. The prestigious Hospital Universitario La Paz (HULP), a large tertiary hospital in Madrid with 1,308 beds, is one of three Spanish hospitals using Steriwave.

According to the latest ECDC HAI surveillance report, the prevalence rate of HAIs in Spain is 8.2% compared to the median of 6.8%. Spain also had higher rates of antibiotic usage, with over 45% of patients with an HAI receiving antibiotics. More than 150,000 patients have been treated with Steriwave to date, and no serious side effects have been reported.

[premium beeks] 08/5/2024 15:39

I doubt it, the investment community aren't all thickets like you.This went to 5p before the current recovery, so likely someone turning a profit. You should try it sometime.

[purple11] 08/5/2024 15:32

2.3m shares sold at 6.50

no doubt placing shares and happy to sell at a loss.

what a dire market this is

[z1co] 08/5/2024 12:15

PATT's real name is Richard Bobath



Conman jailed for swindling £41,000 working at medical charities allowed to work as NHS ambulance driver
Richard Bobath, 54, served ­almost two years for fraud after duping the British Polio Fellowship, which helps desperately sick people, and the British Institute of Radiology


ByDan WarburtonSenior News Reporter

[purple11] 08/5/2024 12:09

zico the clown

one winner.many many complete failures.....